Abstract
Recently, intensive laboratory and preclinical studies have identified and validated therapeutic molecular targets in cancer, particularly the receptor tyrosine kinases, the intracellular pathways, and the genetic and epigenetic alterations, resulting in an unprecedented surge of novel, targeted therapies and therapeutic regimens. There are currently over 30 new agents being tested in the treatment of solid tumors as well as hematologic malignancies. Many of these are novel, targeted agents that have demonstrated significant efficacy and prolonged survival. Here, we discuss the current understanding of the mechanisms of action of novel molecular targeted cancer therapies being tested in the preclinical and clinical settings, including agents that act directly on the cell surface receptors, intracellular signaling pathways, and cell maintenance processes.
Keywords: Small molecule inhibitor, monoclonal antibody, antisense oligonucleotide, ell surface receptors, receptor tyrosine kinase, the intracellular pathway
Anti-Cancer Agents in Medicinal Chemistry
Title: Novel Molecular-Targeted Therapeutics for the Treatment of Cancer
Volume: 8 Issue: 5
Author(s): Hiroshi Yasui and Kohzoh Imai
Affiliation:
Keywords: Small molecule inhibitor, monoclonal antibody, antisense oligonucleotide, ell surface receptors, receptor tyrosine kinase, the intracellular pathway
Abstract: Recently, intensive laboratory and preclinical studies have identified and validated therapeutic molecular targets in cancer, particularly the receptor tyrosine kinases, the intracellular pathways, and the genetic and epigenetic alterations, resulting in an unprecedented surge of novel, targeted therapies and therapeutic regimens. There are currently over 30 new agents being tested in the treatment of solid tumors as well as hematologic malignancies. Many of these are novel, targeted agents that have demonstrated significant efficacy and prolonged survival. Here, we discuss the current understanding of the mechanisms of action of novel molecular targeted cancer therapies being tested in the preclinical and clinical settings, including agents that act directly on the cell surface receptors, intracellular signaling pathways, and cell maintenance processes.
Export Options
About this article
Cite this article as:
Yasui Hiroshi and Imai Kohzoh, Novel Molecular-Targeted Therapeutics for the Treatment of Cancer, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (5) . https://dx.doi.org/10.2174/187152008784533099
DOI https://dx.doi.org/10.2174/187152008784533099 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Role of Cardiovascular Aldosterone in Hypertension
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis
Current Genomics MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Current Chemical Biology Lymphoproliferative Disorders and Chemokines
Current Drug Targets The Evolving AML Genomic Landscape: Therapeutic Implications
Current Cancer Drug Targets KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets Amrubicin: A Synthetic Anthracyclin Analogue in the Treatment of Extensive Stage Small Cell Lung Cancer
Recent Patents on Anti-Cancer Drug Discovery Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors
Current Genomics Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design Carcinogenicity and Chronic Rodent Toxicity of the Selective Progesterone Receptor Modulator Ulipristal Acetate
Current Drug Safety Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab
Recent Patents on Anti-Cancer Drug Discovery Idarubicin and Ara-C Treatment Associated with Fungal Infection in Acute Leukemia Patients with Febrile Neutropenia
Clinical Cancer Drugs Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Targeting Metabolic Enzymes in Cancer – Clinical Trials Update
Current Enzyme Inhibition Past, Recent Progresses and Future Perspectives of Nanotechnology Applied to Antifungal Agents
Current Drug Metabolism Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review
Current Clinical Pharmacology Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)
Current Signal Transduction Therapy Polymers Based on Phenyl Boric Acid in Tumor-Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design